Protara Therapeutics Stock Analysis

TARA Stock  USD 3.01  0.03  0.99%   
Protara Therapeutics is undervalued with Real Value of 10.02 and Target Price of 31.4. The main objective of Protara Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Protara Therapeutics is worth, separate from its market price. There are two main types of Protara Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Protara Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Protara Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

Protara Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protara Therapeutics recorded a loss per share of 2.64. The entity last dividend was issued on the 10th of January 2020. The firm had 1:40 split on the 10th of January 2020. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. Artara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. To find out more about Protara Therapeutics contact the company at 646 844 0337 or learn more at https://www.protaratx.com.

Protara Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Protara Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Protara Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Protara Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Protara Therapeutics currently holds about 98.46 M in cash with (37.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Protara Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 DelveInsight

Protara Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protara Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Protara Largest EPS Surprises

Earnings surprises can significantly impact Protara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-03
2022-09-30-0.76-0.680.0810 
2021-03-11
2020-12-31-0.54-0.440.118 
2023-11-03
2023-09-30-0.98-0.870.1111 
View All Earnings Estimates

Protara Therapeutics Environmental, Social, and Governance (ESG) Scores

Protara Therapeutics' ESG score is a quantitative measure that evaluates Protara Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Protara Therapeutics' operations that may have significant financial implications and affect Protara Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Protara Stock Institutional Investors

Shares
Oppenheimer & Co Inc2024-09-30
179.1 K
Geode Capital Management, Llc2024-09-30
170 K
Ikarian Capital, Llc2024-09-30
155.7 K
Blackrock Inc2024-06-30
115.3 K
Woodline Partners Lp2024-06-30
100 K
Two Sigma Advisers, Llc2024-06-30
80.5 K
Marshall Wace Asset Management Ltd2024-06-30
77.4 K
Bridgeway Capital Management, Llc2024-09-30
49.2 K
Lpl Financial Corp2024-09-30
46 K
Ra Capital Management, Llc2024-09-30
1.9 M
Opaleye Management Inc2024-09-30
1.7 M
Note, although Protara Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Protara Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.71 M.

Protara Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.51)(0.54)
Return On Capital Employed(0.60)(0.63)
Return On Assets(0.51)(0.54)
Return On Equity(0.59)(0.62)

Management Efficiency

Protara Therapeutics has return on total asset (ROA) of (0.2811) % which means that it has lost $0.2811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4591) %, meaning that it created substantial loss on money invested by shareholders. Protara Therapeutics' management efficiency ratios could be used to measure how well Protara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.54. In addition to that, Return On Capital Employed is expected to decline to -0.63. At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 16.9 M, whereas Net Tangible Assets are forecasted to decline to about 71.9 M.
Last ReportedProjected for Next Year
Book Value Per Share 6.03  5.73 
Tangible Book Value Per Share 6.03  5.73 
Enterprise Value Over EBITDA 0.30  0.31 
Price Book Value Ratio 0.31  0.30 
Enterprise Value Multiple 0.30  0.31 
Price Fair Value 0.31  0.30 
Enterprise Value14.3 M13.6 M
The strategic initiatives led by Protara Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta
1.786
Return On Assets
(0.28)
Return On Equity
(0.46)

Technical Drivers

As of the 1st of December, Protara Therapeutics holds the Risk Adjusted Performance of 0.1361, semi deviation of 2.72, and Coefficient Of Variation of 597.56. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protara Therapeutics, as well as the relationship between them.

Protara Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Protara Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Protara Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Protara Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Opaleye Management Inc. over a month ago
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3
 
Jesse Shefferman over a month ago
Insider Trading
 
Opaleye Management Inc. over two months ago
Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3
 
Opaleye Management Inc. over two months ago
Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3
 
Jesse Shefferman over two months ago
Insider Trading
 
Jesse Shefferman over three months ago
Disposition of 3300 shares by Jesse Shefferman of Protara Therapeutics subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 15000 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4034 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 5000 shares by Opaleye Management Inc. of Protara Therapeutics at 2.308 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 2500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.2138 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 2500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.1233 subject to Rule 16b-3
 
Opaleye Management Inc. over three months ago
Disposition of 5000 shares by Opaleye Management Inc. of Protara Therapeutics at 2.0748 subject to Rule 16b-3

Protara Therapeutics Outstanding Bonds

Protara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protara bonds can be classified according to their maturity, which is the date when Protara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Protara Therapeutics Predictive Daily Indicators

Protara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Protara Therapeutics Corporate Filings

13A
18th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
12th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
12th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
10th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
30th of August 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
6th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
18th of July 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Protara Therapeutics Forecast Models

Protara Therapeutics' time-series forecasting models are one of many Protara Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protara Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Protara Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Protara Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Protara shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Protara Therapeutics. By using and applying Protara Stock analysis, traders can create a robust methodology for identifying Protara entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(1.02)(1.07)
Operating Profit Margin(2.31)(2.43)
Net Loss(1.02)(1.07)

Current Protara Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Protara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Protara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
31.4Strong Buy4Odds
Protara Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Protara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Protara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Protara Therapeutics, talking to its executives and customers, or listening to Protara conference calls.
Protara Analyst Advice Details

Protara Stock Analysis Indicators

Protara Therapeutics stock analysis indicators help investors evaluate how Protara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Protara Therapeutics shares will generate the highest return on investment. By understating and applying Protara Therapeutics stock analysis, traders can identify Protara Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow24.9 M
Common Stock Shares Outstanding11.3 M
Total Stockholder Equity68.3 M
Property Plant And Equipment Net6.6 M
Cash And Short Term Investments65.6 M
Cash39.6 M
Accounts Payable2.4 M
Net Debt-34.1 M
50 Day M A2.1766
Total Current Liabilities6.1 M
Other Operating Expenses43.6 M
Non Current Assets Total10.2 M
Non Currrent Assets Other3.7 M
Stock Based Compensation6.1 M

Complementary Tools for Protara Stock analysis

When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios